ArticleArteriosclerosis, thrombosis, and vascular biology2013
Multilocus genetic risk scores for coronary heart disease prediction.
Article in Arteriosclerosis, thrombosis, and vascular biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Genomic prediction of coronary heart disease.European heart journal · 2016Pooled it
- Guideline
- Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.Lancet (London, England) · 2015Pooled it
- Motivation, Perception, and Treatment Beliefs in the Myocardial Infarction Genes (MI-GENES) Randomized Clinical Trial.Journal of genetic counseling · 2017Trial
- Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial).Circulation · 2016Trial
- Susceptibility Loci for Clinical Coronary Artery Disease and Subclinical Coronary Atherosclerosis Throughout the Life-Course.Circulation. Cardiovascular genetics · 2015Trial
- Article
- The Inclusion of Underrepresented Populations in Cardiovascular Genetics and Epidemiology.Journal of cardiovascular development and disease · 2024Review
- A Stacking Framework for Polygenic Risk Prediction in Admixed Individuals.medRxiv : the preprint server for health sciences · 2024Article
- Ethical, legal, and social implications of genetic risk prediction for multifactorial disease: a narrative review identifying concerns about interpretation and use of polygenic scores.Journal of community genetics · 2023Article
- Associations of cardiometabolic polygenic risk scores with cardiovascular disease in African Americans.Research square · 2023Article
- Cardiovascular prevention: sometimes dreams can come true.European heart journal supplements : journal of the European Society of Cardiology · 2023Article
- Article
- Advances and Applications of Polygenic Scores for Coronary Artery Disease.Annual review of medicine · 2023Review
- Cardiovascular prevention: sometimes dreams can come true.European heart journal supplements : journal of the European Society of Cardiology · 2022Article
- Prognostic Modelling Studies of Coronary Heart Disease-A Systematic Review of Conventional and Genetic Risk Factor Studies.Journal of cardiovascular development and disease · 2022Review
- AdaBoost Ensemble Methods Using K-Fold Cross Validation for Survivability with the Early Detection of Heart Disease.Computational intelligence and neuroscience · 2022Article
- Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease in the Asia-Pacific Region.JACC. Asia · 2021Review
- Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps.Nature medicine · 2021Review
- Integrated Polygenic Tool Substantially Enhances Coronary Artery Disease Prediction.Circulation. Genomic and precision medicine · 2021Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
objectiveCurrent guidelines do not support the use of genetic profiles in risk assessment of coronary heart disease (CHD). However, new single nucleotide polymorphisms associated with CHD and intermediate cardiovascular traits have recently been discovered. We aimed to compare several multilocus genetic risk score (MGRS) in terms of association with CHD and to evaluate clinical use. APPROACH AND
resultsWe investigated 6 Swedish prospective cohort studies with 10 612 participants free of CHD at baseline. We developed 1 overall MGRS based on 395 single nucleotide polymorphisms reported as being associated with cardiovascular traits, 1 CHD-specific MGRS, including 46 single nucleotide polymorphisms, and 6 trait-specific MGRS for each established CHD risk factors. Both the overall and the CHD-specific MGRS were significantly associated with CHD risk (781 incident events; hazard ratios for fourth versus first quartile, 1.54 and 1.52; P<0.001) and improved risk classification beyond established risk factors (net reclassification improvement, 4.2% and 4.9%; P=0.006 and 0.017). Discrimination improvement was modest (C-index improvement, 0.004). A polygene MGRS performed worse than the CHD-specific MGRS. We estimate that 1 additional CHD event for every 318 people screened at intermediate risk could be saved by measuring the CHD-specific genetic score in addition to the established risk factors.
conclusionsOur results indicate that genetic information could be of some clinical value for prediction of CHD, although further studies are needed to address aspects, such as feasibility, ethics, and cost efficiency of genetic profiling in the primary prevention setting.
Indexed as
Identifiers
23685553What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.